Literature DB >> 30416772

Clinical predictors of pathologically response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: long term outcomes of a phase II study.

Zihui Tan1,2,3, Hong Yang1,2,3, Jing Wen1,2,3, Kongjia Luo1,2,3, Qianwen Liu1,2,3, Yihuai Hu1,2,3, Lanjun Zhang1,2,3, Mengzhong Liu1,2,4, Jingping Yun2,5, Jianhua Fu1,2,3.   

Abstract

BACKGROUND: A pathologically complete response (pCR) or near pCR to neoadjuvant chemoradiotherapy (NCRT) might imply a better prognosis in patients with esophageal cancer. The aim of the study is to identify clinical factors associated with a pCR or near pCR.
METHODS: We retrospectively analyzed 40 patients with radical esophagectomy after NCRT for esophageal squamous cell carcinoma (ESCC) from January 2001 to December 2006 in Sun Yat-sen University Cancer Center. Clinical factors included age, gender, weight loss, dysphagia, drinking status, smoking status, tumor location, tumor length, tumor grade, cT status, cN status, the regimen of chemotherapy and the interval between NCRT and surgery as potential predictors for a pCR or near pCR. Logistic regression was used to estimate the independent factors for a pCR or near pCR.
RESULTS: After surgical resection, 22.5% of the patients obtained the pCR. Patients with pCR had a better prognosis than those with non-pCR. However, there was no statistically significantly difference between the two groups (P=0.124). We separated the patients into pCR or near pCR (good responders, GRs) and poor responders (PR) based on the histology. GR showed better overall survival (OS) than PR (P=0.014). Univariate analysis indicated that short tumor length, good tumor grade and never drinking were associated with GR to NCRT. Using logistic regression analysis, good tumor grade was the only independent factor for the GR to NCRT (P=0.021). Cox regression revealed that weight loss, drinking status and GR were independent factors in ESCC patients with radical esophagectomy after NCRT.
CONCLUSIONS: Our study indicated that good tumor grade were an independent significant factor for the GR to NCRT. Weight loss, drinking status and GR were independent factors in patients with radical esophagectomy after NCRT. GR may improve OS of ESCC patients receiving NCRT.

Entities:  

Keywords:  Esophageal squamous cell carcinoma (ESCC); neoadjuvant chemoradiotherapy (NCRT); pathologically response

Year:  2018        PMID: 30416772      PMCID: PMC6196203          DOI: 10.21037/jtd.2018.08.88

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  15 in total

1.  Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.

Authors:  George W Dittrick; Jill M Weber; Ravi Shridhar; Sarah Hoffe; Marcovalerio Melis; Khaldoun Almhanna; James Barthel; James McLoughlin; Richard C Karl; Kenneth L Meredith
Journal:  Ann Surg Oncol       Date:  2011-11-02       Impact factor: 5.344

2.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

3.  Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?

Authors:  Helen M Heneghan; Claire Donohoe; Jessie Elliot; Zuhair Ahmed; Vinod Malik; Narayamasamy Ravi; John V Reynolds
Journal:  Ann Surg       Date:  2016-11       Impact factor: 12.969

4.  Molecular Marker Expression Is Highly Heterogeneous in Esophageal Adenocarcinoma and Does Not Predict a Response to Neoadjuvant Therapy.

Authors:  Nathan W Bronson; Brian S Diggs; Gene Bakis; Kenneth M Gatter; Brett C Sheppard; John G Hunter; James P Dolan
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452

5.  Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.

Authors:  Kenneth L Meredith; Jill M Weber; Kiran K Turaga; Erin M Siegel; Jim McLoughlin; Sarah Hoffe; Melis Marcovalerio; Nilay Shah; Scott Kelley; Richard Karl
Journal:  Ann Surg Oncol       Date:  2010-02-06       Impact factor: 5.344

6.  Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer?

Authors:  Anna Lee; Andrew T Wong; David Schwartz; Joseph P Weiner; Virginia W Osborn; David Schreiber
Journal:  Ann Thorac Surg       Date:  2016-05-04       Impact factor: 4.330

7.  Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.

Authors:  S H Lim; M Hong; S Ahn; Y-L Choi; K-M Kim; D Oh; Y C Ahn; S-H Jung; M-J Ahn; K Park; J I Zo; Y M Shim; J-M Sun
Journal:  Eur J Cancer       Date:  2015-11-26       Impact factor: 9.162

8.  Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.

Authors:  Christophe Mariette; Laetitia Dahan; Françoise Mornex; Emilie Maillard; Pascal-Alexandre Thomas; Bernard Meunier; Valérie Boige; Denis Pezet; William B Robb; Valérie Le Brun-Ly; Jean-François Bosset; Jean-Yves Mabrut; Jean-Pierre Triboulet; Laurent Bedenne; Jean-François Seitz
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

9.  Characterization of residual tumours at the primary site in patients with a near pathological complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.

Authors:  Y-K Chao; Y Chang; C-J Yeh; H-K Chang; C-K Tseng; W-Y Chuang
Journal:  Br J Surg       Date:  2016-09-13       Impact factor: 6.939

10.  The influence of preoperative weight loss on the postoperative course after esophageal cancer resection.

Authors:  Maartje K van der Schaaf; Hugo W Tilanus; Jan J B van Lanschot; Asif M Johar; Pernilla Lagergren; Jesper Lagergren; Bas P L Wijnhoven
Journal:  J Thorac Cardiovasc Surg       Date:  2013-09-20       Impact factor: 5.209

View more
  2 in total

1.  Prediction of Locoregional Recurrence-Free Survival of Oesophageal Squamous Cell Carcinoma After Chemoradiotherapy Based on an Enhanced CT-Based Radiomics Model.

Authors:  Jie Kong; Shuchai Zhu; Gaofeng Shi; Zhikun Liu; Jun Zhang; Jialiang Ren
Journal:  Front Oncol       Date:  2021-09-24       Impact factor: 6.244

2.  Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis.

Authors:  Helena Hong Wang; Ellen C de Heer; Jan Binne Hulshoff; Gursah Kats-Ugurlu; Johannes G M Burgerhof; Boudewijn van Etten; John Th M Plukker; Geke A P Hospers
Journal:  Ann Surg Oncol       Date:  2020-11-28       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.